David Lau, PhD
Clinical Cardiac Electrophysiology · New York, NYNPI 1902064421
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $173,050 of the $201,831 with a category attached, or 85.7%. Johnson & Johnson accounts for 72.3% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2019 at $62,838 and has fallen 94.6% since, to $3,416 in 2025. Among clinical cardiac electrophysiology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 882 payments — averaging $228.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$146K
- E.r. Squibb & Sons, L.L.C.$35K
- Boston Scientific$5K
- Pfizer$3K
- Novartis$2K
- Boehringer Ingelheim$2K
- plus $10K from 28 others
What the payments were for
- Consulting fees$2,3501%
- Speaking & faculty fees$173,05086%
- Travel & lodging$7330%
- Food & beverage$25,60213%
- Education$960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 233 | $145,954 |
| E.r. Squibb & Sons, L.L.C. | 109 | $34,896 |
| Boston Scientific | 37 | $4,753 |
| Pfizer | 35 | $2,959 |
| Novartis | 91 | $1,874 |
| Boehringer Ingelheim | 73 | $1,574 |
| Merck | 55 | $1,225 |
| Amarin Pharma, Inc. | 52 | $1,029 |
| Esperion Therapeutics, Inc. | 26 | $900 |
| Abbott | 6 | $883 |
| Medtronic(2 entities) | 7 | $746 |
| Amgen | 23 | $679 |
| Biotronik Inc. | 5 | $662 |
| Sanofi-aventis U.S. LLC | 28 | $620 |
| Bristol Myers Squibb | 1 | $600 |
| AstraZeneca | 23 | $590 |
| Novo Nordisk | 11 | $262 |
| Lexicon Pharmaceuticals, Inc. | 13 | $256 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $247 |
| Cleerly, Inc. | 1 | $188 |
| Bayer | 10 | $173 |
| Heartflow, Inc. | 1 | $145 |
| Regeneron Healthcare Solutions, Inc. | 3 | $127 |
| Scpharmaceuticals Inc. | 4 | $102 |
| Astellas Pharma US Inc | 1 | $90 |
| Lilly USA, LLC | 3 | $65 |
| IBSA Pharma Inc. | 3 | $55 |
| Kowa Pharmaceuticals America, Inc. | 3 | $46 |
| Bard Peripheral Vascular, Inc. | 1 | $33 |
| Azurity Pharmaceuticals, Inc. | 2 | $30 |
| Agepha Pharma FZ LLC | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| AbbVie | 1 | $14 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$143,220
- CAMZYOS$25,762
- ELIQUIS$6,100
- GENERAL - THERAPIES$1,309
- LUX-Dx Insertable Cardiac Monitor$743
- EMBLEM$652
- NEXLIZET$556
- NEXLETOL$556
- BioMonitor$464
- CardioMEMS HF System$329
- EMBLEM MRI S-ICD$299
- Mitra Clip system$283
- RESONATE$259
- Micra$191
- Cleerly Ischemia$188
- Cleerly Labs$188
- Resolute$187
- Acticor 7 VR-T DX$180
- SilverHawk$147
- Watchman$146
How this compares
$201,831 in reported general payments places this provider in the 90th percentile of 214 clinical cardiac electrophysiology providers in New York.
See all clinical cardiac electrophysiology providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VascepaIcosapent Ethyl | 4,572 | $2,234,665 |
| XareltoRivaroxaban | 2,571 | $1,969,202 |
| EliquisApixaban | 2,444 | $1,967,444 |
| EntrestoSacubitril/Valsartan | 1,960 | $1,575,960 |
| Diclofenac Epolamine | 1,086 | $875,397 |
| JardianceEmpagliflozin | 437 | $330,622 |
| CreonLipase/Protease/Amylase | 199 | $140,540 |
| FarxigaDapagliflozin Propanediol | 140 | $138,493 |
| LinzessLinaclotide | 199 | $113,814 |
| CamzyosMavacamten | 12 | $101,774 |
| Repatha SureclickEvolocumab | 103 | $88,066 |
| MultaqDronedarone Hcl | 91 | $79,311 |
| Ranolazine ErRanolazine | 1,827 | $74,329 |
| ZenpepLipase/Protease/Amylase | 42 | $74,285 |
| VerquvoVericiguat | 98 | $73,801 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $145,954 | $1,969,2022,571 claims |
| PfizerEliquis | $2,959 | $1,967,4442,444 claims |
| NovartisEntresto | $1,874 | $1,575,9601,960 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,574 | $344,840453 claims |
| AbbVieCreon, Linzess, Restasis | $14 | $301,085471 claims |
| AstraZenecaFarxiga, Nexium, Brilinta | $590 | $197,210287 claims |
| MerckVerquvo, Janumet, Januvia | $1,225 | $124,847139 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $34,896 | $101,77412 claims |
| Novo NordiskOzempic, Rybelsus | $262 | $101,125110 claims |
| Sanofi-aventis U.S. LLCMultaq | $620 | $79,31191 claims |
| Esperion Therapeutics, Inc.Nexletol | $900 | $55,286127 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $46 | $19,70029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 214 clinical cardiac electrophysiology providers in New York.
Other clinical cardiac electrophysiology in New York
- Vivek ReddyNew York$14.9M
- Jacob KoruthNew York$3.7M
- Srinivas DukkipatiNew York$2.7M
- Amir AhmadiNew York$789K
- Larry ChinitzNew York$448K
- James IpNew York$347K
- Nicholas SkipitarisNew York$293K
- Mohit TuragamNew York$202K
- Christopher LiuNew York$181K
- Chirag BarbhaiyaNew York$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.